Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of daxdilimab in systemic lupus erythematosus
2022-000855-35Phase 2Completed
- Sponsor
- Horizon Therapeutics
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daxdilimab in systemic lupus erythematosus (SLE), sponsored by Horizon Therapeutics. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 1 more. Started Jul 2022; status: completed.
02
Drugs
daxdilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2022-000855-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000855-35.